FREE 2-DAY SHIPPING ON ORDERS $200+

Blog

Retatrutide vs CagriSema: Phase 3 Weight Loss, Side Effects and FDA Status (2026)

Two matching clear glass beakers of clear liquid side by side on a white lab bench in soft window light

Novo Nordisk and Eli Lilly each have a follow-up to their best-selling weight-loss shots. Novo’s is CagriSema, which pairs semaglutide, the drug in Wegovy, with cagrilintide, a long-acting form of the fullness hormone amylin. Lilly’s is retatrutide, a single peptide that reaches three hormone receptors at once.

CagriSema is closer to pharmacies: Novo filed it with the FDA in December 2025 and expects an answer before 2026 is out. Retatrutide has the bigger numbers. Counting everyone who started, its top dose took off 25.0% of starting weight over 80 weeks, against 20.4% for CagriSema over 68, and in February 2026 CagriSema fell short in its own trial against tirzepatide. The two have never been tested against each other.

Simms Research stocks one of them: Retatrutide (GLP-3), in vials from 10mg to 60mg, with its batch certificate posted. CagriSema isn’t carried.

What is CagriSema?

Two drugs given together once a week: semaglutide 2.4mg, the Wegovy dose, and cagrilintide 2.4mg. The name joins the two halves. Novo Nordisk makes both, and in its trials the pair comes in a single-use pen with two chambers (Gulisano, Journal of Diabetes Science and Technology, 2026).

Cagrilintide is the new part. It copies amylin, a hormone the pancreas releases alongside insulin after a meal, which tells the brainstem the stomach is full and slows how fast food leaves it. Cagrilintide reaches the amylin receptors and the closely related calcitonin receptor, and stays active for a full week between doses.

Each half works on its own, and the pair works better. In REDEFINE 1, among people who kept taking their shots, semaglutide alone took off 16.1% over 68 weeks, cagrilintide alone 11.8%, and the two together 22.7% (Garvey, NEJM, 2025). The obesity trials run under the name REDEFINE and the type 2 diabetes trials under REIMAGINE.

Glass separatory funnel on a ring stand by a window holding two clear liquid layers with a visible boundary between them

Difference between CagriSema and retatrutide

They share one target, the GLP-1 receptor, and pick different partners for it. CagriSema adds amylin. Retatrutide adds GIP and glucagon.

CagriSema is two molecules dosed side by side, each built to fit its own receptor. Retatrutide is one 39-amino-acid chain designed to fit three, so the balance between its signals is set in the molecule rather than by two doses. Simms Research’s guide to what retatrutide is covers how that chain was put together.

The bigger split is what the partners do. GLP-1 and amylin both act on appetite and on the stomach, so CagriSema sends two fullness signals to the brain by separate routes and works mostly through eating less. In rats, its weight loss came from lower intake while energy spending held steady (Jacobsen, Nature Metabolism, 2025).

Retatrutide’s extra pieces reach further. GIP is the hormone that lifted tirzepatide above semaglutide, and glucagon pushes the liver to burn fat and keeps the body spending energy; in mice, retatrutide raised energy expenditure outright (Coskun, Cell Metabolism, 2022). The liver is where that third receptor shows most, and Retatrutide for Fatty Liver sets out those scans. CagriSema has no glucagon component.

Retatrutide vs CagriSema for weight loss

Retatrutide took off more in people with and without diabetes, by about five points of body weight in each, though its trials ran 12 weeks longer.

MeasureCagriSema 2.4mg + 2.4mgRetatrutide 12mg
Obesity trialREDEFINE 1: 3,417 adults, 68 weeksTRIUMPH-1: 2,339 adults, 80 weeks
Weight lost, everyone counted20.4%25.0%
Placebo group3.0%3.9%
Weight lost, staying on treatment22.7%28.3%
Type 2 diabetes trialREDEFINE 2: 1,206 adults, 68 weeksTRIUMPH-2: 1,152 adults, 80 weeks
Weight lost with diabetes, everyone counted13.7% (placebo 3.4%)18.8% (placebo 5.1%)

Both companies report two numbers. The first counts everyone randomized, including people who skipped doses or quit; the second counts only those who kept taking the drug. Holding like against like, retatrutide leads on both, and the gap over placebo is wider too: 21.0 points for retatrutide 12mg against 17.3 for CagriSema (Garvey, NEJM, 2025; Jastreboff, NEJM, 2026).

The extra 12 weeks don’t explain the gap. In its smaller Phase 2 trial, retatrutide 12mg had already reached 24.2% by week 48 (Jastreboff, NEJM, 2023), above both of CagriSema’s 68-week figures. At the far end of the range, 40.4% of people who stayed on CagriSema lost a quarter of their weight or more, and 23.1% lost 30% or more.

People with type 2 diabetes lose less on all of these drugs, and both programs show it. Net of placebo, CagriSema 2.4mg + 2.4mg took off 10.3 points in REDEFINE 2 (Davies, NEJM, 2025) and retatrutide 12mg 13.7 in TRIUMPH-2 (Bellido, Lancet, 2026). On blood sugar, 73.5% of the CagriSema group finished with an A1C of 6.5% or lower; retatrutide’s A1C results are set out trial by trial in Retatrutide for Diabetes.

CagriSema vs tirzepatide vs retatrutide

Tirzepatide makes the best yardstick, and CagriSema has already been measured against it directly. Tirzepatide won.

REDEFINE 4 put 809 adults with obesity on CagriSema 2.4mg + 2.4mg or tirzepatide 15mg, the top Zepbound dose, for 84 weeks. Counting everyone, CagriSema took off 20.2% and tirzepatide 23.6%; among people who stayed on, 23.0% against 25.5%. Novo Nordisk had set out to show CagriSema was no worse than tirzepatide, and the result missed that bar (Novo Nordisk, February 23, 2026). In type 2 diabetes, a lower CagriSema dose of 1.0mg + 1.0mg did beat tirzepatide’s starting dose of 5mg, 12.4% against 9.1% at 60 weeks in REIMAGINE 5.

Retatrutide’s own meeting with tirzepatide, TRIUMPH-5, enrolled about 800 adults and is due to finish its main phase in November 2026; no results are out. Until then the comparison runs trial against trial: tirzepatide 15mg reached 20.9% after 72 weeks in SURMOUNT-1 (Jastreboff, NEJM, 2022), below retatrutide’s 25.0% after 80. That puts tirzepatide above CagriSema in a direct test and below retatrutide in separate ones. The retatrutide vs tirzepatide breakdown goes dose by dose.

Simms Research sells tirzepatide as Tirzepatide (GLP-2), from $65 for a 10mg vial to $186 for 60mg.

Retatrutide vs CagriSema side effects

Mostly the stomach on both, worst while the dose is climbing. CagriSema brought more nausea; retatrutide brought more people stopping, plus a skin sensation CagriSema doesn’t cause.

In REDEFINE 1, nausea hit 55% of the CagriSema group and 12.6% of the placebo group, constipation 30.7% and 11.6%, and vomiting 26.1% and 4.1%. Four in five had at least one stomach complaint, twice placebo’s rate, and most were mild to moderate and passed. On retatrutide 12mg in TRIUMPH-1, nausea reached 42.4% against 14.8%, constipation 26.1% against 10.9%, and vomiting 25.3% against 4.8%.

Quitting runs the other way. Over side effects, 5.9% left CagriSema against 3.7% on placebo, while 11.3% left retatrutide 12mg against 4.9%. Part of the gap is the trial design: REDEFINE 1 let investigators hold people on a lower step when the full dose didn’t suit them, and only 57.3% of the CagriSema group were on 2.4mg + 2.4mg at the end, against 70.2% of the semaglutide-only group. TRIUMPH-1 randomized each person to a set dose.

Retatrutide also brings dysesthesia, a tingling or extra-sensitive feeling in the skin, in 12.5% of the 12mg group and 0.9% of the placebo group, and a resting heart rate that climbs with the dose. The retatrutide side effects guide tracks when each one starts and fades.

Overhead view of five small glass weighing bottles on a pale blue bench, each holding a little more white powder than the last

Retatrutide vs CagriSema dosage

Both take 16 weeks to reach the top dose. CagriSema starts at 0.25mg of each drug and climbs to 2.4mg of each; retatrutide starts at 2mg and climbs to 12mg.

CagriSema’s steps raise both drugs together, passing 1.7mg of each at week 12 before the final 2.4mg + 2.4mg, the dose Novo filed. Lower doses hold up well: in REDEFINE 9, 309 adults kept to 1.7mg + 1.7mg or 1.0mg + 1.0mg for 68 weeks, and those who stayed on lost 20.7% and 21.0% against 2.0% on placebo (Wharton, Lancet Diabetes and Endocrinology, 2026). Novo has also planned a Phase 3 trial going the other way: cagrilintide 2.4mg alongside 7.2mg of semaglutide, three times the Wegovy dose.

Retatrutide moves in four-week steps: 2mg, 4mg, 6mg, 9mg, then 12mg from week 16. Its Phase 3 trials settle people on 4mg, 9mg or 12mg, and 9mg took off 23.7% in TRIUMPH-1, 1.3 points short of 12mg. The retatrutide dosage chart lists every week of that climb; for syringe units at a given vial size, use the retatrutide calculator.

The forms differ as well. In its trials, CagriSema comes as Novo’s prefilled pen, one dose per pen. Retatrutide for research comes as freeze-dried powder that is mixed with bacteriostatic water before use, covered step by step in How to Reconstitute Retatrutide.

Empty scientific conference hall in daylight with rows of grey chairs, a plain lectern and a blank white screen

Is CagriSema FDA approved?

Not yet. Novo Nordisk filed CagriSema 2.4mg + 2.4mg for weight management in December 2025 and expects the FDA’s decision in the fourth quarter of 2026.

The filing rests on REDEFINE 1 and REDEFINE 2, and Novo is preparing a US launch for early 2027 if approval comes. A heart outcomes trial, REDEFINE 3, has 7,076 adults with established heart disease on CagriSema or placebo and is still running (Cavender, American Heart Journal, 2026).

CagriSema’s diabetes trials add a blood-sugar case. In REIMAGINE 2, 2,713 adults on metformin took CagriSema, semaglutide or cagrilintide for 68 weeks, and CagriSema lowered A1C by 1.91 points against 1.75 for semaglutide 2.4mg alone (Buse, Lancet Diabetes and Endocrinology, 2026), a gap of 0.16 points.

When will retatrutide be approved?

Lilly’s filing is planned for the first quarter of 2027, with six Phase 3 readouts behind it since December 2025, which leaves CagriSema the nearer of the two to a pharmacy shelf. The retatrutide FDA approval timeline runs from filing to a likely decision.

Retatrutide vs CagriSema: which is better?

For weight loss, retatrutide. It took off more than CagriSema with and without diabetes, and its results sit above tirzepatide’s where CagriSema’s came in below.

CagriSema’s case is real. It should reach pharmacies first, fewer people quit it over side effects, its lower doses kept nearly the whole result, and its semaglutide half already has a heart record: 20% fewer heart attacks, strokes and cardiovascular deaths over about three years in SELECT (Lincoff, NEJM, 2023). Retatrutide’s side of the ledger is the size of the loss, a glucagon arm that clears liver fat, and Phase 3 results in obesity, diabetes, knee arthritis and sleep apnea, with a 10,000-person heart and kidney trial due in 2029.

Simms Research sells Retatrutide (GLP-3) for research in four sizes: $84 for 10mg, $129 for 20mg, $159 for 30mg and $259 for 60mg, or $8.40 a milligram falling to $4.32. The batch on sale was tested on July 16, 2026: three vials labelled 10mg held 10.68mg, purity read 99.611%, and LC-MS matched the molecule’s mass. The full report is on the retatrutide lab results page. At TRIUMPH-1’s 12mg a week, a 60mg vial lasts five weeks; retatrutide cost per month covers the other doses.

Frequently asked questions

Can you take CagriSema and retatrutide together?

No human study has tried it, and both carry a GLP-1 signal, so the pair would stack two of them. The nearest data is in rats: retatrutide given with cagrilintide, CagriSema’s amylin half, took off more weight than either drug alone and more than cagrilintide paired with semaglutide or tirzepatide (Petersen, Nature Metabolism, 2026). Lilly’s own amylin pairing is eloralintide with tirzepatide; Eloralintide vs Retatrutide has those results.

Is CagriSema a GLP-3?

No. CagriSema is a GLP-1 drug, semaglutide, paired with an amylin drug. GLP-3 is the label research shops use for retatrutide, and What Is GLP-3 explains where the name came from.

Does Simms Research sell CagriSema?

No. Its weight-loss peptides are retatrutide and tirzepatide; cagrilintide and semaglutide aren’t in its catalog.

Is Simms Research legit?

Its record is open to checking. Orders go out from Florida, and one placed by 5PM Eastern ships that business day. Each certificate of analysis links to the lab’s original document. Every parcel carries the Free Delivery Guarantee: lost, stolen after a delivery scan or damaged in transit, it is replaced or refunded. Questions reach a person at support@simmsresearch.com or 855-592-8507 between 9AM and 5PM Eastern on weekdays.

Does this page use a discount code?

No code and no affiliate link. The prices above are the regular ones.

Keep exploring

Verify the underlying batch data

Compare published methods and results, then open the source certificate for the batch you are evaluating.

Browse lab results